65,437 trials
Gastrointestinal Mucosal Damage
Primary: Gastromucosal Damage (GMD) Score of Paracetamol Tablet vs Ibuprofen Capsule — 0.33; 1.48 Scores on a scale — p=<0.0001
Varicose Veins
Primary: Weight-adjusted Polidocanol Cmax (Serum) — 584.1; 1188.7; 840.7; 1189.6 ng/mL
Alcohol Dependence
Primary: Number of Very Heavy Drinking Days Per Week — 2.1; 1.3 days
PONV
Primary: Complete Response Rate — 38; 38; 32; 32 participants
Facial Dermatoses · Seborrheic Keratoses
Primary: Percent Clearance of All Lesions — 88; 96; 92.5; 0 percentage of lesion clearance
Obesity
Primary: AUC Post Surgery (n =5) Compared to AUC Control (n=5) — 124.4; 314.8 ng-hr/mL
Posttraumatic Stress Disorder · Depression · Insomnia Disorder
Primary: Depression — 20.30; 19.18 units on a scale — p=<.05
Short Bowel Syndrome
Primary: To Identify Small Intestinal Permeability Changes in Short Bowel Syndrome Patients After Administration of Recombinant Human Growth Hormone (Zorbtive®). — 7 participants
Non-Hodgkin's Lymphoma
Primary: Percentage of Participants With Overall Response At the End of Induction Period — 33.3; 44.6 Percentage of participants — p=0.1587
Overweight and Obesity
Primary: Weight (kg) — 80; 76.6; 74.7; 75 kilograms
Juvenile Justice Involvement · Drug Abuse
Primary: Delinquency — .30; .95 log(units on a scale)
Postpartum Hemorrhage
Primary: Need for Additional Uterotonic Medications — 10; 40 percentage of participants — p=<0.01
Leukemia · Lymphoma · Myelodysplastic Syndrome
Primary: The Cumulative Incidence of Grade II-IV Acute GVHD up to Day 100 After Stem Cell Infusion — 32 Percentage of participants
Acute Myelogenous Leukemia · Lymphoid Leukemia · Chronic Myelogenous Leukemia
Primary: Median Disease-free Survival — 333 Days
Cancer
Primary: Number of Participants With Best Confirmed Response — 0; 1; 0; 13 Participants